Spectrum Pharmaceuticals' Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® National Award Finalist

Spectrum Pharmaceuticals' Chairman and Chief Executive Officer Named Ernst & Young Entrepreneur of the Year® National Award Finalist

<0> Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor Relations </0>

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, has been named an Ernst & Young National Entrepreneur Of The Year 2012 Life Science Finalist. Ernst & Young’s Entrepreneur Of The Year is the country’s most prestigious business award for entrepreneurs. The award encourages entrepreneurial activity and recognizes leaders and visionaries who demonstrate innovation, financial success and personal commitment as they create and build world-class businesses.

"I am honored to have been a finalist for the national E&Y award, having received the Orange County Region Entrepreneur of the Year award last year,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “Our firm has achieved significant progress over the past two years, continuing to diversify our business and lowering financial and clinical risks. We now have three commercial cancer therapies, a robust, maturing pipeline, including two late-stage product candidates and a strong balance sheet. We have achieved a record eight consecutive quarters of profitability. For the first nine months of 2012, total revenues are up 41.2% year over year. This is testament to the dedication and commitment of our teams focusing on critical unmet medical needs and bringing new therapeutic options to patients.”

Dr. Shrotriya was recognized as one of four Finalists in the Life Science category. The Finalists were honored at the Entrepreneur Of The Year Awards gala, the culminating event of the Ernst & Young Strategic Growth Forum® in Palm Springs, Calif. The Forum is the nation’s premier gathering of high-growth, market-leading companies. Awards were given in a total of ten categories. The Ernst & Young Entrepreneur Of The Year Finalists and Award winners were selected by an independent panel of judges from 244 regional award recipients.

Ernst & Young’s Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 140 cities in 50 countries.

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards are nationally sponsored in the United States by SAP America and the Ewing Marion Kauffman Foundation.

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 167,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

For more information, please visit ey.com.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market three oncology drugs ─ FUSILEV (levoleucovorin) for Injection in the U.S.; FOLOTYN (pralatrexate injection), also marketed in the U.S.; and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at .

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.